Health Condition 1: M321- Systemic lupus erythematosus withorgan or system involvement
Conditions
Interventions
Intervention1: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
All India Institute of Medical Sciences Raipur
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients of SLE fulfilling EULAR/ACR criteria. 2. SLE patients either newly diagnosed, or previously diagnosed but not on treatment except prednisolone <10 mg/day or equivalent dose dose of another corticosteroid.
Exclusion criteria
Exclusion criteria: 1. Pregnant and lactating females 2. dose of prednisolone > 10 mg/day or, equivalent dose of another corticosteroid. 3. Patients who received any immunosuppressive medicines in last 6 months 4. Malignancy 5. Patients with chronic hepatitis B,C, or HIV 6. Patients with chronic liver disease or chronic kidney disease 7. Any active infection 8. Presence of diabetic mellitus
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Independent variables- age & gender, SLEDAI score Outcome variables- Level of miRNA, CTGF & fractalkine. Identification of these biomarkers with disease severity can uphold them as non-invasive markers for organ damage and assessment of disease activity. They can serve as predictors of disease progression. Theymight also provide them as potential candidates for the treatment of SLE. Timepoint: 0 3 month 6 month | — |
Secondary
| Measure | Time frame |
|---|---|
| Independent variables - ANA, ANA blot Outcome variables - miR-145, CTGF & FractalkineTimepoint: 0 3 month 6 month | — |
Countries
India
Contacts
Public ContactDr Rachita Nanda
AIIMS Raipur
Outcome results
None listed